Summary

Other Scenarios:

Buyer: sanofi-aventis (ADR) (SNY) Last Price: 41.82 Market Cap.: 113.70B
Target: MedImmune, Inc. (MEDI) Last Price: 57.94 Market Cap.: 13.84B

Lines of Business Summary:

Product Summary:

Overlap & Complementary Sectors

Sector Buyer Target # of Focused Companies
*Healthcare 884
Biopharmaceuticals 342
Medical Devices   246
Veterinary Products and Services   6

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Sample Products in Similar Lines of Business

Sample Products in Complementary Lines of Business
Buyer (Total: 247)
  • Allegra (Fexofenadine Hydrochloride)
  • AVE0675 (Toll-Like Receptor Agonist)
  • SAR 389644 (Prostaglandin D2 Antagonist)
  • Xyzal (Levocetirizine Dihydrochloride)
Target (Total: 36)
  • Siplizumab (Monoclonal Antibody - Formerly MEDI-507)
  • MEDI-545 (Anti-Interferon Alpha Monoclonal Antibody)
  • MDX-1103 (Human Antibodies)
  • MEDI-546 (Anti-Type 1 Interferon Receptor Monoclonal Antibody)
Buyer
  • Rapidpoint ENOX Test
  • Tubersol (Tuberculin Purified Protein Derivative)
  • OptiClik
  • Lantus SoloStar
Target

n/a

Business Relationship Summary:

Top Key Suppliers

Top Key Customers
Buyer (Total: 43)
  • IDM Pharma Inc. (IDMI)
  • Regeneron Pharmaceuticals, Inc. (REGN)
  • Cell Genesys, Inc. (CEGE)
  • Liberty Property Trust (LRY)
Target (Total: 17)
  • Micromet Inc. (MITI)
  • Infinity Pharmaceuticals Inc. (INFI)
  • Critical Therapeutics, Inc. (CRTX)
  • Option Care, Inc. (OPTN)
Buyer (Total: 9)
  • Bristol Myers Squibb Co. (BMY)
  • Cephalon, Inc. (CEPH)
  • King Pharmaceuticals, Inc. (KG)
  • Medicis Pharmaceutical Corporation (MRX)
Target (Total: 10)
  • AmerisourceBergen Corp. (ABC)
  • McKesson Corporation (MCK)
  • Cardinal Health, Inc. (CAH)
  • Abbott Laboratories (ABT)

Key Financial Summary:

Key Metrics

  Buyer Target
Number of Employees 100,289 2,359
Revenue Per Employee 397,277.4 976,913.8
Total Revenue 9,919.0 574.8
Total Expenses 7,502.3 342.4
Other Revenue 341.6 0.0
Cost of Revenue 2,487.4 115.5
SG&A Expense 2,499.4 147.1
Research & Development 1,442.5 79.5
Other Operating Expense -182.8 0.3
Operating Income 2,416.7 232.4
Unusual Income 29.4 0.0
LT Debt to Capital n/a 44.29
Fwd P/E 11.45 64.37
Fwd P/Rev 2.92 9.51
Book Value n/a 1,464.4
Curr Portion of LTD/Cap Lease n/a 0.0

Individual Company Summary

Focused

Buyer

Focused (): *Healthcare > Biopharmaceuticals

Target

Focused (): *Healthcare > Biopharmaceuticals > Infectious Diseases > Viral

Business Description

Buyer

Sanofi-Aventis is a pharmaceutical group engaged in the research, development, manufacture and marketing of healthcare products. Its business includes two main activities: pharmaceuticals and human vaccines. In pharmaceutical activity, Sanofi-Aventis specializes in six therapeutic areas: thrombosis, cardiovascular, metabolic disorders, oncology, central nervous system and internal medicine. In the human vaccines activity, it offers vaccines in five areas: pediatric combination vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines and travel vaccines. As of April 4, 2007, Sanofi-Aventis announced that Acomplia has been approved by Swissmedic, the Swiss Agency for therapeutics products, in association with a light hypocaloric diet and physical activity for obese patients or for overweight patients with at least one associated cardiovascular risk factor, after insufficient weight reduction following physical activity or alimentary adaptation.

Target

MedImmune, Inc. is a biotechnology company focusing its efforts on the therapeutic areas of infectious disease, cancer and inflammatory disease. The Company primarily develops monoclonal antibodies and vaccines. MedImmune markets three products: Synagis (palivizumab) and FluMist (Influenza Virus Vaccine Live, Intranasal) to help prevent two common respiratory infectious diseases, and Ethyol (amifostine) to help reduce adverse side effects of certain anti-cancer chemotherapies and radiotherapies. The Company is also developing a pipeline of product candidates for potential commercialization. MedImmune operates facilities in the United States and Europe to manufacture and distribute one or more components of each of its products. The Company has established clinical, research, development, manufacturing and commercialization collaborations with other companies and organizations. In December 2006, MedImmune sold all rights to the CytoGam product line and related assets to ZLB Behring AG.

Deal Summary

Key Ratios

  Buyer Target
Gross Margin % 74.27 76.35
Operating Margin % 16.37 11.19
Quick Ratio 0.11 3.64
Current Ratio 1.18 3.98
Coverage Ratio -0.02 0.61
Total Assets 106,197.3 3,033.5
Return on Equity % 8.66 11.04
Return on Assets % 5.08 5.33
Cash+ ST Inv. Per Share 0.58 4.3
Total Debt 9,483.1 1,164.1
Total Debt to Equity % 15.23 79.49
Total Debt to Tangible Equity % n/a 91.37
Debt to Asset % 8.93 38.37

Product Summary

Sector Buyer Target
*Healthcare
Biopharmaceuticals
Allergies
The Allergies Subsector includes therapeutics that treat exaggerated immune reaction induced by exposure to a foreign substance.
  
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
  
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
  
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
  
Hematology
The Hematology Subsector includes therapeutics that treat blood-based diseases and disorders.
  
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
  
Obstetrics/Gynecology
The Obstetrics/Gynecology Subsector includes therapeutics that treat female genital disorders, pregnancy, and childbirth.
  
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
Ophthalmology
The Ophthalmology Subsector includes therapeutics that treat eye disorders, infections, inflammations and irritations.
  
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
  
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
Surgery
The Surgery Subsector includes therapeutics that treat complications associated with surgical procedures.
  
Toxicology
The Toxicology Subsector includes therapeutics that treat harmful effects from exposure to toxic substances; narcotics, nicotine and alcohol withdrawal therapeutics are also included in this sector.
  
Urology
The Urology Subsector includes therapeutics that treat diseases of the kidney, urinary tract, bladder, and the male reproductive system.
  
Weight Management
The Weight Management Subsectors includes herapeutics that treat and manage weight disorders.
  
Medical Devices  
Clinical Diagnostics
The Clinical Diagnostics Subsector includes medical devices that analyze human body specimens within a medical setting. These devices, including equipment, biological and chemical reagents are primarily used for the diagnosis of diseases.
  
Drug Delivery
The Drug Delivery Subsector includes medical devices that facilitate the delivery of medications through different anatomical entryways, including blood vessels, skin, the mouth, and the lungs. Common devices in this sector include vascular access catheters, needles, implants, and inhalers.
  
Orthopedics
The Orthopedics Subsector includes medical devices that diagnose and treat musculoskeletal diseases involving muscles, bones and joints.
  
Plastic/Reconstructive Surgery
The Plastic/Reconstructive Surgery Subsector includes medical devices that treat and modify a patient's external appearance.
  
Veterinary Products and Services  
Veterinary Pharmaceuticals
The Veterinary Pharmaceuticals Subsector includes companies that manufacture veterinary pharmaceuticals and vaccines for the prevention and treatment of veterinary diseases.

Buyer Products:

  • Merial Group Ltd.
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Product Details

Sector Buyer Target
*Healthcare
Biopharmaceuticals
Allergies  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for treatment of allergic reactions in early stages of clinical research where human subject is involved.

Buyer Products:

  • Allegra (Fexofenadine Hydrochloride)
  • AVE0675 (Toll-Like Receptor Agonist)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of allergic reactions in very early stages of research where no human subject is involved.

Buyer Products:

  • SAR 389644 (Prostaglandin D2 Antagonist)
  
Upper Respiratory  
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.

Buyer Products:

  • Allegra (Fexofenadine Hydrochloride)
  • Xyzal (Levocetirizine Dihydrochloride)
  
Antihistamines/Decongestants
Therapeutics that block the inflammatory action of histamines and relieve or prevent coughs.

Buyer Products:

  • Allegra-D 24 Extended-Release (Fexofenadine HCl/Pseudoephedrine HCl)
  • Allegra-D (Fexofenadine/Pseudoephedrine)
  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation using a steroidal compound.

Buyer Products:

  • Nasacort HFA (Triamcinolone Acetonide) Nasal Aerosol
  • Nasacort AQ Nasal Spray (Triamcinolone Acetonide)
  • Nasacort Nasal Inhaler (Triamcinolone Acetonide)
  
Cardiovascular System  
Heart Disorders  
Acute Coronary Syndrome (ACS)  
Anticoagulating Agents  
Platelet Aggregation Inhibitors  
Adenosine Diphosphate (ADP) Inhibitors
Therapeutics that treat angina by inhibiting the action of adenosine diphosphate (ADP), which in turn inhibits the aggregation of platelets.

Buyer Products:

  • Plavix (Clopidogrel Bisulfate)
  
Angina  
Anticoagulating Agents  
Thrombin Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing blood clots from forming.

Buyer Products:

  • Lovenox (Enoxaparin Sodium)
  
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat chest pains by inhibiting stimulation of beta adrenergic receptors of the heart muscle.

Buyer Products:

  • Kerlone (Betaxolol Hydrochloride)
  
Arrhythmia  
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat abnormal rhythm of the heart beat by inhibiting the stimulation of beta adrenergic receptors of the heart muscle.

Buyer Products:

  • Sectral (Acebutolol Chlohydrate)
  
Calcium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of calcium into heart muscle cells.

Buyer Products:

  • Cardizem Injectable (Diltiazem Hydrochloride)
  
Sodium Channel Blocking Agents/Potassium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of sodium and potassium into heart muscle cells.

Buyer Products:

  • Cordarone (Amiodarone Hydrochloride)
  • Multaq (Dronedarone)
  
Heart Failure (HF)  
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat the ineffective pumping of the heart by inhibiting the renin-angiotensin system.

Buyer Products:

  • Delix/Tritace (Ramipril)
  
Complications  
Edema  
Loop Diuretic Agents
Therapeutics that treat the excessive accumulation of fluids by increasing the excretion of sodium, potassium, chloride ions, and water in urine.

Buyer Products:

  • Lasix (Furosemide)
  
Inotropic/Vasodilatory Agents
Therapeutics that treat acute heart failure by increasing intracellular ionized calcium and contractile force in cardiac muscle and relaxing vascular muscle.

Buyer Products:

  • Primacor (Milrinone Lactate)
  
Myocardial Infarction (MI)  
Anticoagulating Agents  
Platelet Aggregation Inhibitors  
Adenosine Diphosphate (ADP) Inhibitors
Therapeutics that treat irreversible damage to the heart muscle by inhibiting the action of adenosine diphosphate (ADP), which in turn inhibits the aggregation of platelets.

Buyer Products:

  • Plavix (Clopidogrel Bisulfate)
  
Thrombin Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing blood clots from forming.

Buyer Products:

  • Lovenox (Enoxaparin Sodium)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • SR 123781 (Hexadecasaccharide)
  • SSR 149744 (Celivarone)
  • XRP0673 (Otamixaban)
  • AVE3247 (Factor X Inhibitor)
  • AVE5026 (Indirect Xa/IIa Inhibitor)
  • XRP0038 (Plasmid Based Gene Therapy)
  • AVE0657 (NHE-3 Inhibitor)
  • HMR1069 (Guanylate Cyclase Activator)
  • AVE9488 (e-NOS Transcription Enhancer)
  • AVE3085 (e-NOS Transcription Enhancer)
  • AVE1231 (Potassium Channel Blocking Agent)
  • AVE-7688 (Ilepatril)
  • SL 65.0472 (Serotonin Receptor Antagonist)
  • Ataciguat/HMR1766 (Guanylate Cyclase Activator)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • SAR 407899 (Rho Kinase Inhibitor)
  • SSR 128428 (Hexadecasaccharide/Indirect Xa/IIa Inhibitior)
  • SAR 377142 (Oral Factor X Inhibitor)
  • SAR 114646 (Antiarrhythmic Agent)
  • SSR 128429 (Indirect Xa/IIa IInhibitor)
  
Vascular Disorders  
Atherosclerosis  
Platelet Aggregation Inhibitors  
Adenosine Diphosphate (ADP) Inhibitors
Therapeutics that treat the narrowing or hardening of the arteries by inhibiting the action of adenosine diphosphate (ADP), which in turn inhibits the aggregation of platelets.

Buyer Products:

  • Plavix (Clopidogrel Bisulfate)
  
Deep Vein Thrombosis (DVT)  
Anticoagulating Agents (Anticoagulants)  
Thrombin Inhibitors
Therapeutics that prevent or treat clots in blood vessels by preventing blood clots from forming.

Buyer Products:

  • Idraparinux
  • Biotinylated Idraparinux
  • Lovenox (Enoxaparin Sodium)
  
Hypertension  
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat high blood pressure by inhibiting the renin-angiotensin system.

Buyer Products:

  • Delix/Tritace (Ramipril)
  
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)/Calcium Channel Blockers
Therapeutics that treat high blood pressure by inhibiting the renin-angiotensin system and preventing the entry of calcium into heart muscle cells.

Buyer Products:

  • Teczem (Enalapril/Diltiazem)
  
Angiotensin II Receptor Antagonists
Therapeutics that treat high blood pressure by blocking the angiotensin II receptor.

Buyer Products:

  • Aprovel/Avapro (Irbesartan)
  
Angiotensin II Receptor Antagonists/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by blocking the angiotensin II receptor and increasing the excretion of sodium ions, potassium ions, and water through urine.

Buyer Products:

  • Avalide (Irbesartan/Hydrochlorothiazide)
  
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle.

Buyer Products:

  • Sectral (Acebutolol Chlohydrate)
  • Kerlone (Betaxolol Hydrochloride)
  
Calcium Channel Blocking Agents
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine.

Buyer Products:

  • Cardizem SR (Diltiazem Hydrochloride)
  
Loop Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of sodium, potassium, chloride ions, and water in urine.

Buyer Products:

  • Lasix (Furosemide)
  
Hypovolemia  
Plasma Volumizers  
Albumin-Based
Therapeutics based on plasma proteins that treat a decrease in circulating fluid (plasma) in the body by increasing plasma volume.

Buyer Products:

  • Albuminar (Human Albumin)
  
Peripheral Vascular Disease  
Blood Viscosity Reducing Agents
Therapeutics that treat arterial obstruction outside of the heart by altering the flow of red blood cells.

Buyer Products:

  • Trental (Pentoxifylline)
  
Stroke  
Anticoagulating Agents (Anticoagulants)  
Platelet Aggregation Inhibitors  
Adenosine Diphosphate (ADP) Inhibitors
Therapeutics that prevent or treat damage to nerve cells of the brain by preventing platelets from clumping together.

Buyer Products:

  • Plavix (Clopidogrel Bisulfate)
  
Thromboembolism  
Anticoagulating Agents (Anticoagulants)  
Thrombin Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing blood clots from forming.

Buyer Products:

  • Lovenox (Enoxaparin Sodium)
  • Biotinylated Idraparinux
  • Idraparinux
  
Dermatology
Acne  
Rosacea  
Emollients
Therapeutics that treat chronic inflammatory disorder of the face characterized by redness and pimple formation by moisturizing and softening the skin.

Buyer Products:

  • Dermik Laboratories Noritate (Metronidazole)
  
Para Aminobenzoic Acid (PABA) Inhibitors
Therapeutics that treat chronic inflammatory disorder of the face characterized by redness and pimple formation by inhibiting bacterial folic acid synthesis.

Buyer Products:

  • Dermik Laboratories Sulfacet R (Sodium Sulfacetamide/Sulfur)
  
Vulgaris  
Antibacterial Agents  
Lincosamides
Therapeutics that treat acne vulgaris caused by bacterial infection by inhibiting bacterial protein synthesis.

Buyer Products:

  • Dermik Laboratories BenzaClin (Clindamycin/Benzoyl Peroxide)
  
Macrolides
Therapeutics that treat acne vulgaris caused by bacterial infection by inhibiting RNA-dependent bacterial protein synthesis.

Buyer Products:

  • Dermik Laboratories Benzamycin (Erythromycin/Benzoyl Peroxide)
  
Keratolytic Agents
Therapeutics that soften, separate, and cause the shedding of skin.

Buyer Products:

  • Dermik Laboratories Benzagel (Benzoyl Peroxide)
  
Para Aminobenzoic Acid (PABA) Inhibitors
Therapeutics that treat bacterial infections of the skin by inhibiting a bacterial enzyme responsible for synthesis of folic acid.

Buyer Products:

  • Dermik Laboratories Klaron (Sodium Sulfacetamide)
  • Dermik Laboratories Sulfacet R (Sodium Sulfacetamide/Sulfur)
  
Lesion/Scaling Disorders  
Actinic Keratoses  
Antimetabolite Agents  
Pyrimidine Analogs
Therapeutics that treat actinic keratoses by blocking the synthesis of DNA.

Buyer Products:

  • Dermik Laboratories Carac (5-Fluorouracil)
  
Chronic Urticaria  
Antihistamines
Therapeutics that treat allergic skin conditions by blocking the action of histamines.

Buyer Products:

  • Xyzal (Levocetirizine Dihydrochloride)
  • Allegra (Fexofenadine Hydrochloride)
  
Dermatitis  
Atopic (Eczema)  
Emollients
Topical therapeutics that soothe and soften the skin.

Buyer Products:

  • Dermik Laboratories Noritate (Metronidazole)
  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat atopic dermatoses by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site.

Buyer Products:

  • Dermik Laboratories Psorcon E (Diflorasone Diacetate)
  
Seborrheic (Dandruff)  
Para Aminobenzoic Acid (PABA) Inhibitors
Therapeutics that treat bacterial infections of the skin by inhibiting a bacterial enzyme responsible for synthesis of folic acid.

Buyer Products:

  • Dermik Laboratories Sulfacet R (Sodium Sulfacetamide/Sulfur)
  
Dermatoses  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site.

Buyer Products:

  • Dermik Laboratories Psorcon E (Diflorasone Acetate)
  • Dermik Laboratories Dermatop Emollient Cream (Prednicarbate)
  
Psoriasis  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site.

Buyer Products:

  • Dermik Laboratories Psorcon E (Diflorasone Diacetate)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of skin disorders in early stages of clinical research where human subject is involved.

Target Products:

  • Siplizumab (Monoclonal Antibody - Formerly MEDI-507)
  • MEDI-545 (Anti-Interferon Alpha Monoclonal Antibody)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of skin disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • DL6063 (Topical Clindamycin Analogue/BPO)
  
Digestive System  
Gastrointestinal Tract Disorders  
Gastroesophageal Disorders  
Nausea/Vomiting  
Serotonin Receptor Antagonists
Therapeutics that treat nausea and vomiting by blocking the serotonin receptors.

Buyer Products:

  • Anzemet (Dolasetron Mesylate)
  
Liver Disorders  
Cirrhosis  
Complications  
Edema  
Loop Diuretic Agents
Therapeutics that prevent edema by excretion of sodium, potassium, chloride ions, and water in urine.

Buyer Products:

  • Lasix (Furosemide)
  
Vasopressin Antagonists
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by decreasing water reabsorption through the reduction in cellular permeability of the collecting ducts, resulting in an increase in urine volume and decreased osmolality.

Buyer Products:

  • SR 121463 (Satavaptan)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • SR 140333 (Nolpitantium Besilate)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • SSR 241586 (NK3/NK2 Antagonist)
  
Endocrinology/Metabolism  
Diabetes  
Induced Complications  
Central Diabetes Insipidus  
Antidiuretic Agents
Therapeutics that treat prevent the lose of water in the urine.

Buyer Products:

  • DDAVP (Desmopressin Acetate)
  
Nephropathy  
Angiotensin II Receptor Antagonists
Therapeutics that treat diabetes induced kidney disese by blocking the angiotensin II receptor.

Buyer Products:

  • Aprovel/Avapro (Irbesartan)
  
Insulin Dependent Diabetes Mellitus (IDDM)/Type 1 Diabetes  
Insulin Therapy  
Recombinant Human
Therapeutics that are derived from human genes.

Buyer Products:

  • Human Insulin
  • Lantus (Insulin Glargine)
  • Apidra (Insulin Glulisine [rDNA origin] Injection)
  
Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes  
Cannabinoid Receptor Antagonists
Therapeutics that treat non-insulin dependent diabetes by blocking endogenous cannabinoid binding to neuronal CB1 receptors.

Buyer Products:

  • Zimulti (Rimonabant)/Formerly Acomplia
  
Insulin Stimulating Agents (Sulfonylureas)
Therapeutics that treat non-insulin dependent diabetes by stimulating the secretion of insulin.

Buyer Products:

  • DiaBeta (Glyburide)
  • Amaryl (Glimepiride)
  
Insulin Therapy  
Recombinant Human
Therapeutics that are derived from human genes.

Buyer Products:

  • Apidra (Insulin Glulisine [rDNA origin] Injection)
  • Human Insulin
  • Lantus (Insulin Glargine)
  
Intermediary Metabolism Disorders  
Gout  
Hyperuricemia  
Urate Oxidases
Therapeutics that reduce excess uric acid by catalyzing enzymatic oxidation of uric acid into an inactive and soluble metabolite.

Buyer Products:

  • Elitek (Rasburicase)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • AVE-0010 (Glucagons-Like Peptide-1 Receptor Agonist)
  • AVE8134 (PPAR-Alpha Agonist)
  • AVE5530 (Cholesterol Absorption Inhibitor)
  • AVE-7688 (Ilepatril)
  • AVE0897 (PPAR Agonist)
  • AVE1625 (CB1 Receptor Antagonist)
  • AVE0847 (PPAR Agonist)
  • AVE2268 (SGLT2 Inhibitor)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • SAR7226 (SGLT Inhibitor)
  • SAR 351034 (PPAR Agonist)
  • SAR 502250 (TPK1-GSK3 Beta Inhibitior)
  
Hematology  
Hemophilia  
Hemophilia A  
Clotting Agents
Therapeutics that aid in blood coagulation.

Buyer Products:

  • Bioclate (Recombinant Antihemophilic Factor)
  • Helixate NexGen/FS (Recombinant Antihemophilic Factor)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of hematological disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • AVE0847 (PPAR Agonist)
  • AVE8134 (PPAR-Alpha Agonist)
  • AVE1625 (CB1 Receptor Antagonist)
  • AVE5530 (Cholesterol Absorption Inhibitor)
  
Red Blood Cell (RBC) Disorders  
Anemia  
Recombinant Human Erythropoietins
Therapeutics that treat conditions characterized by reduced delivery of oxygen to body tissues by stimulating red blood cell production.

Buyer Products:

  • Dynepo (Erythropoietin)
  
Serum Factor Disorders  
Hyperuricemia  
Urate Oxidases
Therapeutics that reduce excess uric acid by catalyzing enzymatic oxidation of uric acid into an inactive and soluble metabolite.

Buyer Products:

  • Elitek (Rasburicase)
  
Hyponatremia  
Vasopressin Antagonists
Therapeutics that treat hyponatremia by decreasing water reabsorption through the reduction in cellular permeability of the collecting ducts, resulting in an increase in urine volume and decreased osmolality.

Buyer Products:

  • SR 121463 (Satavaptan)
  
Immunology
Autoimmune Disorders  
Arthritis  
Rheumatoid Arthritis (RA)  
Disease Modifying Anti-Rheumatic Drugs (DMARD)  
Pyrimidine Synthesis Inhibitors
Therapeutics that alter or delay the rate of chronic joint inflammation by blocking the overproduction of immune cells.

Buyer Products:

  • Arava (Leflunomide)
  
Multiple Sclerosis (MS)  
Immunomodulators
Therapeutics that treat a neurodegenerative disease characterized by the gradual accumulation of plaques on the nerve sheaths by altering the immune mechanisms.

Buyer Products:

  • HMR 1726 (Teriflunomide)
  • Copaxone (Glatiramer Acetate)
  
Psoriasis  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat a chronic autoimmune disease characterized by softening, separating, causing the shedding of the horny layer of the skin with a steroidal compound.

Buyer Products:

  • Dermik Laboratories Psorcon E (Diflorasone Diacetate)
  
Immune Deficiency Disorders  
Hereditary Angioedema  
Gonadotropin Inhibitors
Therapeutics that treat swelling under the skin caused by the absence of an essential immune regulator by increasing levels of C4 complement component.

Buyer Products:

  • Danocrine (Danazol)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • AVE1701 (CCR1 Antagonist)
  • SSR 150106 (Cytokine Inhibitor)
  • SR 140333 (Nolpitantium Besilate)
  • AVE9897 (CCR1 Antagonist)

Target Products:

  • MEDI-545 (Anti-Interferon Alpha Monoclonal Antibody)
  • Siplizumab (Monoclonal Antibody - Formerly MEDI-507)
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in very early stages of research where no human subject is involved.

Target Products:

  • Siplizumab (Monoclonal Antibody - Formerly MEDI-507)
  • MDX-1103 (Human Antibodies)
  • MEDI-546 (Anti-Type 1 Interferon Receptor Monoclonal Antibody)
  • Anti-Chitinase MAb
  • Anti-CD19/Anti-CD20/Anti-CD22 Monoclonal Antibodies
  • Anti-HMGB1 Monoclonal Antibody
  • Anti-ICOS MAbs
  
Infectious Diseases
Bacterial  
Antibacterial Agents  
Broad Spectrum  
Antibiotics  
Cephalosporin Derivatives
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis.

Buyer Products:

  • Claforan (Cefotoxime Sodium)
  
Glycopeptides
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis.

Buyer Products:

  • Targocid (Teicoplanin)
  
Ketolides
Therapeutics that treat a wide variety of infections by inhibiting RNA-dependent bacterial protein synthesis.

Buyer Products:

  • Ketek (Telithromycin)
  
Narrow Spectrum  
Neurology  
Meningitis  
Antitubercular Agents
Therapeutics that treat inflammation of the lining of the brain and spinal cord by inhibiting bacterial and mycobacterial RNA synthesis.

Buyer Products:

  • Rifadin (Rifampin)
  
Respiratory System  
Respiratory Tract Infections  
Quinolones/Fluoroquinolones
Therapeutics that treat bacterial infections of the air passage involved in breathing, including the trachea, lungs and bronchi by promoting breakage of bacterial DNA strands.

Buyer Products:

  • Zagam (Sparfloxacin)
  
Tuberculosis  
Antitubercular Agents
Therapeutics that treat a bacterial infection of the lung by inhibiting bacterial and mycobacterial RNA synthesis.

Buyer Products:

  • Rifamate (Rifampin/Isoniazid)
  • Rifater (Rifampin/Isoniazid/Pyrazinamide)
  • Rifadin (Rifampin)
  • Priftin (Rifapentine)
  
Urology  
Urinary Tract Infections (UTI)  
Antibacterial Agents (Antibiotics)  
Formaldehyde Precursors
Therapeutics that prevent bacterial infections of the urinary tract by forming formaldehyde, a compound that denatures bacterial proteins.

Buyer Products:

  • Hiprex (Methenamine Hippurate)
  
Quinolones/Fluoroquinolones
Therapeutics that treat bacterial infections of the urethra, urinary bladder, ureters, and kidneys by promoting breakage of bacterial DNA strands.

Buyer Products:

  • Neggram (Nalidixic Acid)
  
Vaccines  
Bacterial  
Combination  
Diphtheria/Tetanus (DT)
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause diphtheria and tetanus.

Buyer Products:

  • Imovax DT
  • DT Pediatric Adsorbed
  • Decavac (Tetanus and Diphtheria Toxoids Adsorbed for Adult Use)
  
Diphtheria/Tetanus/Acellular Pertussis (DTaP)
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause diphtheria, tetanus, and acellular pertussis.

Buyer Products:

  • Tripedia (DTaP)
  • Adacel
  
Diphtheria/Tetanus/Pertussis (DTP)
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause diphtheria, tetanus, and pertussis.

Buyer Products:

  • Daptacel
  • DPT Adsorbed
  
Single Target  
Meningitis
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause meningitis.

Buyer Products:

  • Menactra Toddler
  • Menactra Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
  • Menomune
  • Imovax Meningo A+C
  
Tetanus
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause tetanus.

Buyer Products:

  • Tetanus Toxoid
  • Tet Tox Pl
  
Typhoid Fever
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause typhoid fever.

Buyer Products:

  • TYPHIM VI
  
Bacterial/Viral
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to a bacterial or viral pathogen.

Buyer Products:

  • Unifive (DTP-HepB-Hib Vaccine)
  • Hexaxim (DTP-HepB-Polio-Hib Vaccine)
  • ActHIB
  • Pentacel
  • TetraCOQ
  • Imovax DPT Polio
  • DT Polio
  • TriHIBit
  
Mycological (Fungal)
Antifungal Agents
Narrow Spectrum
Dermatology  
Onychomycosis (Nail)  
Azoles  
Triazoles
Therapeutics that treat fungal infections of the nail by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Buyer Products:

  • Dermik Laboratories Penlac (Ciclopirox)
  
Respiratory System  
Pneumocystis Carinii Pneumonia (PCP)  
Dihydrofolate Reductase Inhibitors
Therapeutics that treat infections of the lungs of immunocompromised patients caused by Pneumocystis carinii by blocking the action of dihydrofolate reductase.

Target Products:

  • Neutrexin (Trimetrexate Glucuronate)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in early stages of clinical research where human subject is involved.

Buyer Products:

  • Pneumo
  • Flu Cell Vaccine
  • SSR 97193 (Ferroquine)
  • Meningococcal A,C,Y,W Infant
  • Meninge B
  • CMV Vaccine
  • Dengue Vaccine
  • XRP2868 (Oral Streptogramins)
  • Flu Pandemia
  • H7N1 Vaccine
  • DTP-HepB-Polio-Hib Vaccine

Target Products:

  • RSV/Anti-Human Metapneumovirus (hMPV)/Parainfluenzavirus (PIV) Vaccine
  • Anti-Human Metapneumovirus Monoclonal Antibody
  • RSV Vaccine
  • Epstein-Barr Virus (EBV) Vaccine
  • Streptococcus pneumoniae Vaccine
  • Intranasal H5N1 Influenza Vaccine
Protozoal  
Antiprotozoal Agents  
Narrow Spectrum  
Malaria  
Quinines
Therapeutics that treat parasitic infections caused by Plasmodia in red blood cells by disrupting replication and transcription.

Buyer Products:

  • Plaquenil (Hydroxychloroquine Sulfate)
  • Primaquine Posphate
  • Aralen (Chloroquine Phosphate)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in very early stages of research where no human subject is involved.

Buyer Products:

  • Yellow Fever Vaccine
  • Malaria Vaccine
  • SAR 97276
  • C. Trachomatis Vaccine
  • SAR 21609 (TRL9 Agonist)
  • SAR 116242
  • Rabies Vaccine

Target Products:

  • EphA2 Antagonists
  • Streptococcus pneumoniae Vaccine
  • Anti-Candida HP Monoclonal Antibody
  • Anti-Staphylococcal HP Monoclonal Antibody
  • Anti-RSV Drug
  • Third Generation Respiratory Syncitial Virus (RSV) Monoclonal Antibody
  • Anti-HMGB1 Monoclonal Antibody
Viral
RNA Viruses  
Paramyxovirus  
Respiratory Syncytial Virus (RSV)  
Immunoglobulins
Therapeutics that treat viral infections in the respiratory tracts of infants with a variety of specific protein that neutralizes the virus.

Target Products:

  • RespiGam (Respiratory Syncytial Virus Immune Globulin Intravenous)
  
Monoclonal Antibodies
Therapeutics that treat viral infections in the respiratory tracts of infants with a neutralizing protein that targets a specific site on the virus.

Target Products:

  • Numax (Anti-RSV MAb)
  • Synagis (Palivizumab)
  • Liquid Synagis (Palivizumab)
  
Vaccines
Bacterial/Viral
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to a bacterial and viral pathogens.

Buyer Products:

  • Unifive (DTP-HepB-Hib Vaccine)
  • TriHIBit
  • Pentacel
  • TetraCOQ
  • ActHIB
  • Imovax DPT Polio
  • Hexaxim (DTP-HepB-Polio-Hib Vaccine)
  • DT Polio
  
Viral
Combination  
Measles/Mumps/Rubella
Therapeutics that prevent or treat viral infections by producing or artificially increasing immunity to measles, mumps, and rubella.

Buyer Products:

  • Trimovax
  
Measles/Rubella
Therapeutics that prevent or treat viral infections by producing or artificially increasing immunity to measles and rubella. .

Buyer Products:

  • RUDI-ROUVAX
  
Single Target
Influenza (Flu)
Therapeutics that prevent or treat viral infections of the respiratory tract by producing or artificially increasing immunity to the Influenza virus.

Buyer Products:

  • Fluzone (Influenza Virus Vaccine)
  • Flu Infants Vaccine
  • Avian Flu (H5N1) Vaccine

Target Products:

  • FluMist (Influenza Virus Vaccine Live, Intranasal)
  • FluMist Refrigerated Formualtion (Influenza Vaccine Live, Intranasal)
Japanese Encephalitis
Therapeutics that prevent or treat viral infections characterized by inflammation of the brain by producing or artificially increasing immunity to the Japanese B Encephalitis virus.

Buyer Products:

  • JE-VAX (Japanese Encephalitis Virus Vaccine)
  • ChimeriVax-JE
  
Measles
Therapeutics that prevent or treat viral infections characterized by a red rash by producing or artificially increasing immunity to the measles virus.

Buyer Products:

  • Imovax Sarampion
  
Papillomavirus
Therapeutics that prevent or treat viral infections characterized by the proliferation of epithelial cells, leading to the formation of warts and possibly other related diseases such as cervical pre-cancers and cervical cancer.

Buyer Products:

  • Gardasil (Quadrivalent Human Papillomavirus Recombinant Vaccine)
  
Polio
Therapeutics that prevent or treat viral infections that attack motor neurons of the brainstem and spinal cord by producing or artificially increasing immunity to the poliovirus

Buyer Products:

  • Imovax Polio
  • IPOL (Poliovirus Vaccination)
  
Rabies
Therapeutics that prevent or treat viral infections that infect brain cells by producing or artificially increasing immunity to the rabies virus.

Buyer Products:

  • Imogam Rabies HT
  • Imovax Rabies Vero
  
Rubella (German Measles)
Therapeutics that prevent or treat viral infections that begin in the lower respiratory tract and lead to a rash by producing or artificially increasing immunity to the rubella virus.

Buyer Products:

  • Imovax Rubeola
  
Yellow Fever
Therapeutics that prevent or treat viral infections characterized by fever and hemorrhage by producing or artificially increasing immunity to the yellow fever virus.

Buyer Products:

  • Stamaril/YF-Vax
  
Musculoskeletal System
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of skeletal system disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • AVE9897 (CCR1 Antagonist)
  • SAR 479746/MLNM 0415 (Oral IKK-Beta Inhibitor)
  • Icatibant (Bradykinin B2 Antagonist)
  • AVE1701 (CCR1 Antagonist)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of skeletal system disorders in very early stages of research where no human subject is involved.

Target Products:

  • Anti-HMGB1 Monoclonal Antibody
  • Siplizumab (Monoclonal Antibody - Formerly MEDI-507)
  
Skeletal Disorders  
Bone Disorders  
Osteoporosis  
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat osteoporosis by preventing loss of bone mass due to osteoclasts.

Buyer Products:

  • Actonel (Risedronate Sodium)/Once Weekly Actonel/Actonel With Calcium
  
Paget`s Disease  
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat paget's disease by inhibiting the loss of bone material by osteoclasts.

Buyer Products:

  • Skelid (Tiludronate Disodium)
  • Actonel (Risedronate Sodium)/Once Weekly Actonel/Actonel With Calcium
  
Joint Disorders  
Rheumatoid Arthritis (RA)  
Disease Modifying Anti-Rheumatic Drugs (DMARD)  
Pyrimidine Synthesis Inhibitors
Therapeutics that alter or delay the rate of chronic joint inflammation by blocking the overproduction of immune cells.

Buyer Products:

  • Arava (Leflunomide)
  
Neurology  
Neurological Disorders  
Alzheimer`s Disease  
Serotonin Receptor Agonists/Nerve Growth Factor (NGF) Agonists
Therapeutics that treat Alzheimer's Disease by stimulating the serotonin receptors and the nerve growth factors.

Buyer Products:

  • Xaliproden
  
Epilepsy  
Partial Seizures  
Complex  
Adjunctive Therapy  
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid, which prevent nerve activation.

Buyer Products:

  • Depakine (Valproate Sodium)
  
Monotherapy  
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid, that prevents nerve activation.

Buyer Products:

  • Depakine (Valproate Sodium)
  
Primary Generalized Seizures  
Absence (Petit Mal)  
Adjunctive Therapy  
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Petit Mal Seizures by preventing the uptake of molecules that prevents nerve activation.

Buyer Products:

  • Depakine (Valproate Sodium)
  
Monotherapy  
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Petit Mal Seizures by preventing the uptake of molecules that prevents nerve activation.

Buyer Products:

  • Depakine (Valproate Sodium)
  
Neuromuscular Disorders  
Multiple Sclerosis (MS)  
Immunomodulators
Therapeutics that treat multiple sclerosis by changing the actions of the immune system.

Buyer Products:

  • HMR 1726 (Teriflunomide)
  • Copaxone (Glatiramer Acetate)
  
Myasthenia Gravis (MG)  
Cholinesterase Inhibitors
Therapeutics that treat Myasthenia Gravis by maintaining the transmission of nerve impulses by inhibiting the enzyme that breaks down acetylcholine.

Buyer Products:

  • Mytelase (Ambenonium Chloride)
  
Neuropathy  
Serotonin Receptor Agonists/Nerve Growth Factor (NGF) Agonists
Therapeutics that treat neuropathy by stimulating the serotonin receptors and the nerve growth factors.

Buyer Products:

  • Xaliproden
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • AVE8488 (5HT-2A Antagonist)
  • M100907 (Volinanserin)
  • AVE8112 (PDE-4 Inhibitor)
  • SR 57667 (Paliroden)
  • SSR 125543 (CRF1 Antagonist)
  • SSR 149415 (Vasopressin Antagonist)
  • SSR 180575 (PBR Ligand)
  • SSR 180711 (Alpha7 Nicotinic Agonist)
  • SSR 411298 (FAAH Inhibitor)
  • AVE1625 (CB1 Receptor Antagonist)
  • AVE9897 (CCR1 Antagonist)
  • SSR 101010 (FAAH Inhibitor)
  
Psychiatric Disorders  
Childhood/Adolescent Disorders  
Enuresis (Bedwetting)  
Antidiuretic Agents
Therapeutics that treat enuresis by suppressing the passing of urine.

Buyer Products:

  • DDAVP (Desmopressin Acetate)
  
Mood Disorders  
Depression  
Beta Adrenergic Receptor Agonists
Therapeutics that treat depression by stimulating neuronal activity in the prefontal cortex area of the brain.

Buyer Products:

  • SR 58611 (Amibegron)
  
Neurokinin-2 Receptor Antagonists
Therapeutics that treat depression by blocking the effects of NK-2, a neuropeptide that may modify serotonin and norepinephrine levels in the nervous system.

Buyer Products:

  • SR 48968 (Saredutant)
  
Tricyclic Compounds
Therapeutics that treat depression by increasing the synaptic concentrations of norepinephrine and serotonin.

Buyer Products:

  • Norpramin (Desipramine Hydrochloride)
  
Sleep Disorders  
Insomnia  
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat insomnia by enhancing the inhibitory action of gamma-aminobutyric acid.

Buyer Products:

  • Ambien (Zolpidem Tartrate)
  • Ambien CR (Zolpidem Extended Release)
  
Serotonin Receptor Antagonists
Therapeutics that treat insomnia by inhibiting the action of serotonin.

Buyer Products:

  • SR 147778 (Eplivanserin)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • SAR 502250 (TPK1-GSK3 Beta Inhibitior)
  • SSR 241586 (NK3/NK2 Antagonist)
  • SAR 110894 (H3 Antagonist)
  • SSR 103800 (GLTY-1 Inhibitor)
  • SSR 126374 (CRF-1 Inhibitor)
  • SSR 102779 (NK-2 Antagonist)
  • SAR 501788 (PBR Ligand)
  
Obstetrics/Gynecology  
Female Genital Disorders  
Endometriosis  
Gonadotropin Inhibitors
Therapeutics that treat endometriosis by preventing the release of the pituitary gland hormone, gonadotropin.

Buyer Products:

  • Danocrine (Danazol)
  
Fibrocystic Breast Disease  
Gonadotropin Inhibitors
Therapeutics that treat fibrocystic breast disease by preventing the release of the pituitary gland hormone, gonadotropin.

Buyer Products:

  • Danocrine (Danazol)
  
Infertility  
Hormonal Treatments  
Ovulation Stimulating Agents
Therapeutics that treat infertility by stimulating the ovaries to release a mature egg.

Buyer Products:

  • Clomid (Clomiphene Citrate)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of female reproductive disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • SSR 126768 (Oxytocin Receptor Anatgonist)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of female reproductive disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • SAR 150640 (Beta 3-Adrenoreceptor Agonist)
  
Oncology
Breast Cancer  
Localized  
Antimicrotubule Agents
Therapeutics that treat and manage breast cancers by blocking the normal function of microtubules, thus inhibiting cell division.

Buyer Products:

  • Taxotere (Docetaxel)
  
Metastatic  
Antimicrotubule Agents
Therapeutics that treat and manage cancers of the breast that have spread beyond their original tumor site by blocking the normal function of microtubules, thus inhibiting cell division.

Buyer Products:

  • XRP9881 (Larotaxel)
  • Taxotere (Docetaxel)
  
Digestive System  
Colon Cancer/Colorectal Cancer  
Metastatic  
Alkylating Agents  
Platinum-Based Agents
Platinum containing therapeutics that are meant to treat and manage colorectal cancers that have spread beyond their original tumor site by interacting with DNA to inhibit cell division.

Buyer Products:

  • Eloxatin (Oxaliplatin)
  
Gastric Cancer (Stomach Cancer)  
Localized  
Antimicrotubule Agents
Therapeutics that treat and manage cancers of the stomach by blocking the normal function of microtubules, thus inhibiting cell division.

Buyer Products:

  • Taxotere (Docetaxel)
  
Pyrimidine Analogs
Therapeutics that treat and manage cancers of the stomach by inhibiting the production of DNA.

Buyer Products:

  • S-1 (Tegafur/Gimeracil/Oteracil)
  
Metastatic  
Alkylating Agents  
Platinum-Based Agents
Platinum containing therapeutics that are meant to treat and manage stomach cancers that have spread beyond their original tumor site by interacting with DNA to inhibit cell division.

Buyer Products:

  • Eloxatin (Oxaliplatin)
  
Pancreatic Cancer  
Metastatic  
Alkylating Agents  
Platinum-Based Agents
Platinum containing therapeutics that are meant to treat and manage pancreatic cancers that have spread beyond their original tumor site by interacting with DNA to inhibit cell division.

Buyer Products:

  • Eloxatin (Oxaliplatin)
  
Antimicrotubule Agents
Therapeutics that treat and manage cancers of the pancreas blocking the normal function of microtubules, thus inhibiting cell division.

Buyer Products:

  • XRP9881 (Larotaxel)
  
Head/Neck Cancer
Localized  
Antimicrotubule Agents
Therapeutics that treat and manage primary tumors of the head and neck by blocking the normal function of microtubules, thus inhibiting cell division.

Buyer Products:

  • Taxotere (Docetaxel)
  
Palliative Agents  
Thiophosphate Cytoprotective Agents
Therapeutics that treat nephropathy associated with repeated cisplatin treament for head and neck cancers.

Target Products:

  • Ethyol (Amifostine)
  
Hematology  
Leukemia (White Blood Cell Cancer)  
Lymphoid  
Acute  
Lymphoblastic  
Asparaginases
Therapeutics that treat and manage rapidly progressing cancers of immature lymphocytic cells by breaking down asparagine which is necessary for cell survival.

Buyer Products:

  • Oncaspar (Pegaspargase)
  
Chronic  
Lymphocytic (CLL)  
Cyclin-Dependent Kinase Inhibitors
Therapeutics that treat and manage slowly progressing cancers of lymphocytic cells by interferring with cyclin-dependent kinase which regulates cell cycle and division.

Buyer Products:

  • Alvocidib (Flavopiridol)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.

Buyer Products:

  • UVIDEM (Cell-Based Vaccine)
  • XRP6258 (Taxoid, Tubulin Inhibitor)
  • aflibercept (VEGF Trap (Vascular Endothelial Growth Factor Antagonist))
  • SSR 244738 (Antitumoral Agent)
  • AVE1642 (Anti-IGF)
  • AVE9633 (Monoclonal Antibody)
  • AVE8062 (Combretastatin Derivative)

Target Products:

  • MT103/MEDI-538 (T-Cell Engager)
  • Siplizumab (Monoclonal Antibody - Formerly MEDI-507)
  • Intravenous IPI-504 (Hsp90 inhibitor)
  • Ethyol (Amifostine)
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer and are currently in an early research or preclinical stage of development.

Buyer Products:

  • Melanoma Vaccine
  • SSR 250411 (Antimitotic Agent)
  • SAR 412988 (Multiple Angiokinase Inhibitor)
  • SAR 103168 (Multikinase Inhibitor)
  • SAR 566658
  • SSR 106462/CEP 11981 (Antitumoral Agent)
  • Colorectal Cancer Vaccine
  • SSR 97225 (Antimitotic Agent)
  • SAR3419 (Tubulin Inhibitor)

Target Products:

  • Anti-EphB4/Anti-EphrinB2 Antibodies
  • cMET Receptor Antagonists
  • EphA4 Agonists
  • Anti-CD19/Anti-CD20/Anti-CD22 Monoclonal Antibodies
  • Anti-ALK Monoclonal Antibody
  • EphA2 Antagonists
  • Siplizumab (Monoclonal Antibody - Formerly MEDI-507)
  • Hedgehog Antagonist
  • Anti-Chitinase MAb
Respiratory System/Thoracic
Lung Cancer
Non Small Cell Lung Cancer (NSCLC)
Antimicrotubule Agents
Therapeutics that treat and manage cancers of the lung including squamous cell carcinoma, adenocarcinoma and large cell carcinoma by blocking the normal function of microtubules, thus inhibiting cell division.

Buyer Products:

  • Taxotere (Docetaxel)
  
Hypoxic Cytotoxins
Therapeutics that treat lung cancer by targeting only cells with very low concentrations of oxygen.

Buyer Products:

  • Tirapazamine
  
Palliative Agents  
Thiophosphate Cytoprotective Agents
Therapeutics that treat nephropathy associated with repeated cisplatin treatment for cancers of the lung including squamous cell carcinoma, adenocarcinoma and large cell carcinoma

Target Products:

  • Ethyol (Amifostine)
  
Urology
Cervical Cancer  
Localized  
Papillomavirus Vaccines
Therapeutics that are meant to promote an immune response against the Papillomavirus that are involved in the pathogenesis of cervical cancer.

Buyer Products:

  • Gardasil (Quadrivalent Human Papillomavirus Recombinant Vaccine)
  
Kidney Cancer (Renal Cell Carcinoma)  
Metastatic  
Vaccines
Therapeutics that are meant to treat and manage advanced and metastatic cancers of the kidneys by eliciting a specific immune response against the cancer cells.

Buyer Products:

  • Trovax (5T4 Tumor Antigen Cancer Vaccine)
  
Ovarian Cancer  
Palliative Agents  
Thiophosphate Cytoprotective Agents
Therapeutics that treat nephropathy associated with repeated cisplatin treatment for cancers of the ovaries.

Target Products:

  • Ethyol (Amifostine)
  
Prostate Cancer  
Metastatic  
Androgen Receptor Blockers
Therapeutics that treat and manage prostate cancers that have spread beyond their original tumor site by binding to the androgen receptors in target tissue thus inhibiting the action of androgens.

Buyer Products:

  • Eligard (Leuprolide Acetate)
  • Nilandron (Nilutamide)
  
Antimicrotubule Agents
Therapeutics that treat and manage cancers of the prostate by blocking the normal function of microtubules, thus inhibiting cell division.

Buyer Products:

  • XRP6258 (Taxoid, Tubulin Inhibitor)
  • Taxotere (Docetaxel)
  
Urinary Bladder Cancer  
Papillocarcinoma  
Vaccines
Therapeutics that are meant to promote an immune response against a patient's bladder cancer.

Buyer Products:

  • TheraCys (BCG Live)
  
Transitional Cell Carcinoma  
Vaccines
Therapeutics that treat and mange cancers arising from the lining of the bladder by stimulating the bodies immune system to combat the cancer.

Buyer Products:

  • TheraCys (BCG Live)
  
Vulvar Cancer  
Squamous Cell Carcinoma  
Papillomavirus Vaccines
Therapeutics that promote an immune response against the Papillomavirus that are involved in the pathogenesis of vaginal and vulvar cancers.

Buyer Products:

  • Gardasil (Quadrivalent Human Papillomavirus Recombinant Vaccine)
  
Ophthalmology  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of eye disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • aflibercept (VEGF Trap (Vascular Endothelial Growth Factor Antagonist))
  
Pain Management  
Narcotics  
Analgesics/Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alters the both the perception of pain as well as the emotional response to pain.

Buyer Products:

  • Talacen (Pentazocine Hydrochloride)
  • Talwin (Pentazocine And Naloxone Hydrochlorides)
  
Opioid Analgesics
Therapeutics that treat pain by providing the body with a milder opioid substitute.

Buyer Products:

  • Demerol (Meperidine Hydrochloride)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of pain in early stages of clinical research where human subject is involved.

Buyer Products:

  • SSR 240612 (Bradykinin B1 Antagonist)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of pain in very early stages of research where no human subject is involved.

Buyer Products:

  • SAR 115740 (TRPV1 Antagonist)
  • SAR 407899 (Rho Kinase Inhibitor)
  
Respiratory System
Lower Respiratory Tract Disorders (Lung Disorders)  
Asthma  
Acute Treatments  
Bronchodilators  
Alpha Adrenergic Receptor Agonists/Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.

Buyer Products:

  • Broncholate (Ephedrine HCl/Guaifenesin)
  
Prophylactic Treatments  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat asthma by reducing inflammation in the lung passages with steroids.

Buyer Products:

  • Alvesco (Ciclesonide)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Allegra (Fexofenadine Hydrochloride)
  • Ketek (Telithromycin)
  • ALVESCO (Ciclesonide)/AVE2635 (Formoterol)
  • AVE0675 (Toll-Like Receptor Agonist)
  • AVE8923 (Tryptase B Inhibitor)

Target Products:

  • BIW-8405 (IL-5 Monoclonal Antibody)
  • MEDI-528 (IL-9 Monoclonal Antibody)
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • SAR 389644 (Prostaglandin D2 Antagonist)
  • AVE8680 (IKK Inhibitor)
  • AVE0657 (NHE-3 Inhibitor)
  • SSR 161421 (Adenosine 3 Antagonist)
  • SAR 21609 (TRL9 Agonist)
  • SAR 398171
  
Upper Respiratory Tract Disorders  
Coughs/Colds  
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.

Buyer Products:

  • Xyzal (Levocetirizine Dihydrochloride)
  • Allegra (Fexofenadine Hydrochloride)
  
Antihistamines/Decongestants
Therapeutics that block the inflammatory action of histamines and reduces the amount of mucous build up.

Buyer Products:

  • Allegra-D (Fexofenadine/Pseudoephedrine)
  
Decongestants/Expectorants
Therapeutics that treat coughs and colds by reducing mucous build up and help in ejection of mucous.

Buyer Products:

  • Zephrex/Zephrex LA (Pseudoephedrine HCI, Guaifenesin)
  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress the inflammation in the upper respiratory tract with steroidal compounds.

Buyer Products:

  • Nasacort Nasal Inhaler (Triamcinolone Acetonide)
  • Nasacort AQ Nasal Spray (Triamcinolone Acetonide)
  • Nasacort HFA (Triamcinolone Acetonide) Nasal Aerosol
  
Surgery  
General  
Complications  
Nausea/Vomiting  
Serotonin Receptor Antagonists
Therapeutics that prevent or treat post surgical nausea and vomiting by blocking the receptors that bind serotonin, a neurotransmitter.

Buyer Products:

  • Anzemet (Dolasetron Mesylate)
  
Musculoskeletal System  
Deep Vein Thrombosis (DVT)  
Anticoagulating Agents (Anticoagulants)  
Thrombin Inhibitors
Therapeutics that treat vascular obstructions due to platelets and cell matter by blocking an enzyme involved in the clotting process.

Buyer Products:

  • Idraparinux
  • Lovenox (Enoxaparin Sodium)
  
Toxicology  
Animal Poisoning  
Scorpions  
Immunoglobulins
Therapeutics that treat scorpion bites with target specific proteins that neutralize the poison.

Buyer Products:

  • LABS 50
  
Snakes  
Immunoglobulins
Therapeutics that treat snake bites with target specific proteins that neutralize the poison.

Buyer Products:

  • ANTIREPT Pasteur
  • Pasteur IPSER Africa
  • Pasteur IPSER Europe
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of toxicity in early stages of clinical research where human subject is involved.

Buyer Products:

  • SR 14778 (Surinabant)
  
Substance Abuse  
Withdrawal  
Nicotine (Smoking Cessation)  
Cannabinoid Receptor Antagonists
Therapeutics that treat nicotine withdrawal by blocking endogenous cannabinoid binding to neuronal CB1 receptors.

Buyer Products:

  • Zimulti (Rimonabant)/Formerly Acomplia
  
Nicotinic Receptor Agonists
Therapeutics that treat nicotine withdrawal by activating nicotine receptors thus reducing cravings for nicotine.

Buyer Products:

  • NicoDerm CQ (Nicotine Transdermal System)
  • SSR 591813 (Dianicline)
  • Nicorette (Nicotine Polacrilex Gum)
  
Urology  
Male Genital Disorders  
Prostate  
Benign Prostate Hyperplasia (BPH)  
Alpha Adrenergic Receptor Blocking Agents (Alpha Blockers)
Therapeutics that increase blood flow by acting on the alpha adrenergic receptors thus causing the smooth muscle in the prostate to relax and decreasing the constriction on the urinary tract.

Buyer Products:

  • Uroxatral/Xatral OD (Alfuzosin) Extended-Release
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of urological disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • SSR 240600 (NK1 Antagonist)
  • AVE-7688 (Ilepatril)
  
Urological Disorders  
Bladder  
Urinary Retention  
Alpha Adrenergic Receptor Blocking Agents (Alpha Blockers)
Therapeutics that treat the sudden inability to pass urine by increasing blood flow and decreasing the constriction on the urinary tract.

Buyer Products:

  • Uroxatral/Xatral OD (Alfuzosin) Extended-Release
  
Kidney (Renal)  
Chronic Renal Failure (CRF)  
Complications  
Anemia  
Recombinant Human Erythropoietins
Therapeutics that treat the condition resulting from the scarcity of red blood cells by inducing the production of red blood cells.

Buyer Products:

  • Dynepo (Erythropoietin)
  
Edema  
Loop Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissues by promoting the excretion of urine.

Buyer Products:

  • Lasix (Furosemide)
  
Diabetic Nephropathy  
Angiotensin II Receptor Antagonists
Therapeutics that treat diabetes induced kidney disese by blocking the angiotensin II receptor.

Buyer Products:

  • Aprovel/Avapro (Irbesartan)
  
Weight Management  
Obesity  
Cannabinoid Receptor Antagonists
Therapeutics that suppress appetite by blocking endogenous cannabinoid binding to neuronal CB1 receptors.

Buyer Products:

  • Zimulti (Rimonabant)/Formerly Acomplia
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of weight disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Antiobesics
  • AVE1625 (CB1 Receptor Antagonist)
  • SR 14778 (Surinabant)
  
Medical Devices  
Clinical Diagnostics  
Hemostasis/Coagulation  
Reagents  
Test Kits  
Specialty Assays
Test kits used to assay for special, esoteric coagulation factors..

Buyer Products:

  • Rapidpoint ENOX Test
  
Immunoassays  
Reagents  
Test Kits  
Bacterial  
Tuberculosis
Immunoassay test kits which quantitatively measure tuberculosis antibody in plasma or serum.

Buyer Products:

  • Tubersol (Tuberculin Purified Protein Derivative)
  
Drug Delivery  
Percutaneous (Subcutaneous/Intramuscular/Intravenous)  
Automatic Injectors
Pen-shaped medical devices used to contain and deliver liquid medications to a specified needle depth with a press of a button.

Buyer Products:

  • OptiClik
  
Syringes  
Specialty  
Insulin
Syringes designed for the delivery of insulin for diabetic patients

Buyer Products:

  • Lantus SoloStar
  
Orthopedics  
Treatment  
Pain Management  
Joint/Region Specific  
Knee  
Viscosupplementation
Devices used to mimic the synovial fluid in the knee joint in order to relieve pain associated with osteoarthritis.

Buyer Products:

  • Hyalgan (Sodium Hyaluronate)
  
Plastic/Reconstructive Surgery  
Surgical  
Procedure/Region Specific  
Implants  
Facial  
Injectable  
Polymer-Based
Injectable implants composed of polymers, or plastics.

Buyer Products:

  • Dermik Laboratories SCULPTRA (Injectable Poly-L-Lactic Acid)
  
Veterinary Products and Services  
Veterinary Pharmaceuticals
The Veterinary Pharmaceuticals Subsector includes companies that manufacture veterinary pharmaceuticals and vaccines for the prevention and treatment of veterinary diseases.

Buyer Products:

  • Merial Group Ltd.
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Relationship Details

Key Competitors

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  Pfizer Inc. n/a 185,773.425 9.98 12.27 3.78 3.88 6.62
Roche Holding Ltd. (ADR) n/a 152,846.074 23.37 19.55 4.38 3.77 6.56
GlaxoSmithKline plc (ADR) n/a 150,489.154 14.15 13.27 3.32 3.23 14.40
Novartis AG (ADR) n/a 130,940.797 23.99 16.65 3.43 3.42 3.23
Genentech, Inc. n/a 81,094.091 33.82 28.67 8.00 6.85 9.67
AstraZeneca plc (ADR) n/a 77,549.535 12.55 12.58 2.84 2.73 8.20
Amgen, Inc. n/a 68,453.847 22.37 14.31 4.64 4.51 14.25
Eli Lilly & Co. n/a 65,456.964 28.01 16.98 4.04 3.68 7.18
Bristol Myers Squibb Co. n/a 60,537.680 38.78 21.16 3.42 3.01 16.56
Novavax, Inc. n/a 196.858 n/a -6.70 48.65 38.83 3.71
Vical Incorporated n/a 195.559 n/a -5.49 18.84 18.49 1.96
Iomai Corporation n/a 52.552 n/a -1.82 25.43 4.08 1.47
Buyer
  Pfizer Inc. n/a 185,773.425 9.98 12.27 3.78 3.88 6.62
Roche Holding Ltd. (ADR) n/a 152,846.074 23.37 19.55 4.38 3.77 6.56
Target
  Pfizer Inc. n/a 185,773.425 9.98 12.27 3.78 3.88 6.62
Johnson & Johnson n/a 181,816.951 17.62 15.46 3.28 2.98 15.54
Roche Holding Ltd. (ADR) n/a 152,846.074 23.37 19.55 4.38 3.77 6.56
GlaxoSmithKline plc (ADR) n/a 150,489.154 14.15 13.27 3.32 3.23 14.40
Novartis AG (ADR) n/a 130,940.797 23.99 16.65 3.43 3.42 3.23
sanofi-aventis (ADR) n/a 113,703.100 20.78 11.45 2.82 2.92 n/a
Genentech, Inc. n/a 81,094.091 33.82 28.67 8.00 6.85 9.67
AstraZeneca plc (ADR) n/a 77,549.535 12.55 12.58 2.84 2.73 8.20
Amgen, Inc. n/a 68,453.847 22.37 14.31 4.64 4.51 14.25
Eli Lilly & Co. n/a 65,456.964 28.01 16.98 4.04 3.68 7.18
Bristol Myers Squibb Co. n/a 60,537.680 38.78 21.16 3.42 3.01 16.56

- Defined by the Company - Defined by Others

Dependent Suppliers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  Human Genome Sciences n/a 1,365.526 n/a -5.98 48.47 26.89 7.89
Buyer
  IDM Pharma Inc. 99.00% 60.694 n/a -3.98 5.12 5.13 6.08
Regeneron Pharmaceuticals, Inc. 75.40% 1,240.691 n/a -10.73 20.33 14.93 6.31
Cell Genesys, Inc. 43.60% 282.330 n/a -2.03 114.66 17.62 10.04
Liberty Property Trust 1.10% 4,168.519 19.31 14.14 6.09 5.81 2.22
The Procter & Gamble Company n/a 197,028.168 20.08 20.60 2.63 2.58 n/a
Pfizer Inc. n/a 185,773.425 9.98 12.27 3.78 3.88 6.62
Teva Pharmaceutical Industries Ltd (ADR) n/a 31,840.000 16.79 17.90 3.61 3.47 23.48
Target
  Micromet Inc. 19.00% 82.856 n/a -2.53 3.16 5.32 26.73
Infinity Pharmaceuticals Inc. 18.00% 208.108 n/a -9.56 8.71 9.09 3.43
Critical Therapeutics, Inc. 10.00% 104.389 n/a -3.05 7.30 4.67 2.25
Option Care, Inc. 9.50% 535.901 22.65 20.26 0.75 0.66 16.40
Seattle Genetics, Inc. 9.30% 564.933 n/a -14.03 46.30 29.38 6.92
PDL BioPharma Inc. 8.00% 2,877.777 n/a 73.88 6.67 5.94 24.10
Abbott Laboratories n/a 84,288.496 54.40 19.28 3.73 3.72 n/a
Baxter International Inc. n/a 37,709.816 24.84 21.71 3.54 3.43 8.34
Cardinal Health, Inc. n/a 26,906.163 19.93 20.66 0.31 0.31 7.77
Becton, Dickinson and Co. n/a 18,677.709 24.39 20.13 3.11 2.96 5.58
Medarex, Inc. n/a 1,924.479 n/a -62.54 40.86 41.21 3.45
Human Genome Sciences n/a 1,365.526 n/a -5.98 48.47 26.89 7.89
Applix, Inc. n/a 255.585 25.58 40.35 4.48 3.79 12.00
Dyax Corp. n/a 223.889 n/a -3.64 17.58 13.74 10.98
Cerus Corporation n/a 196.206 n/a -5.07 5.90 11.01 2.07
SM&A n/a 131.566 33.71 17.50 1.69 1.44 4.31
Avalon Pharmaceuticals, Inc. n/a 65.589 n/a -2.92 22.49 19.33 2.88

- Defined by the Company - Defined by Others

Key Customers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Bristol Myers Squibb Co. n/a 60,537.680 38.78 21.16 3.42 3.01 16.56
Cephalon, Inc. n/a 5,552.009 25.65 20.61 3.01 3.10 32.11
King Pharmaceuticals, Inc. n/a 5,158.354 14.56 12.15 2.55 2.53 4.40
Medicis Pharmaceutical Corporation n/a 1,747.912 79.51 26.78 4.73 3.83 5.73
Regeneron Pharmaceuticals, Inc. n/a 1,240.691 n/a -10.73 20.33 14.93 6.31
Grupo Casa Saba, S.A. (ADR) n/a 853.323 12.02 n/a 0.41 n/a 1.93
VIVUS, Inc. n/a 294.133 n/a 2.44 16.65 n/a 6.05
Introgen Therapeutics, Inc n/a 174.923 n/a -5.80 140.11 34.98 4.76
VaxGen, Inc. n/a 53.301 n/a -1.39 1.78 3.75 2.21
Target
  AmerisourceBergen Corp. 29.00% 9,647.715 19.56 19.88 0.15 0.15 6.93
McKesson Corporation 18.00% 18,039.456 19.76 18.84 0.19 0.18 5.76
Cardinal Health, Inc. 15.00% 26,906.163 19.93 20.66 0.31 0.31 7.77
Abbott Laboratories 12.00% 84,288.496 54.40 19.28 3.73 3.72 n/a
GlaxoSmithKline plc (ADR) n/a 150,489.154 14.15 13.27 3.32 3.23 14.40
Merck & Co., Inc. n/a 109,945.758 23.81 17.14 4.78 4.69 6.80
Medco Health Solutions Inc. n/a 22,523.128 26.18 23.05 0.52 0.49 n/a
Option Care, Inc. n/a 535.901 22.65 20.26 0.75 0.66 16.40
GTC Biotherapeutics, Inc. n/a 90.373 n/a -2.74 9.66 12.98 3.21
Government - United States n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Key Partners

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  GlaxoSmithKline plc (ADR) n/a 150,489.154 14.15 13.27 3.32 3.23 14.40
Novartis AG (ADR) n/a 130,940.797 23.99 16.65 3.43 3.42 3.23
Merck & Co., Inc. n/a 109,945.758 23.81 17.14 4.78 4.69 6.80
Abbott Laboratories n/a 84,288.496 54.40 19.28 3.73 3.72 n/a
Teva Pharmaceutical Industries Ltd (ADR) n/a 31,840.000 16.79 17.90 3.61 3.47 23.48
Becton, Dickinson and Co. n/a 18,677.709 24.39 20.13 3.11 2.96 5.58
Human Genome Sciences n/a 1,365.526 n/a -5.98 48.47 26.89 7.89
Crucell N.V. (ADR) n/a 1,323.323 n/a -32.79 12.95 4.36 3.46
Buyer
  The Procter & Gamble Company n/a 197,028.168 20.08 20.60 2.63 2.58 n/a
TOTAL S.A. (ADR) n/a 191,029.232 12.75 10.76 1.08 1.15 3.72
Target
  GlaxoSmithKline plc (ADR) n/a 150,489.154 14.15 13.27 3.32 3.23 14.40
Novartis AG (ADR) n/a 130,940.797 23.99 16.65 3.43 3.42 3.23
sanofi-aventis (ADR) n/a 113,703.100 20.78 11.45 2.82 2.92 n/a
Merck & Co., Inc. n/a 109,945.758 23.81 17.14 4.78 4.69 6.80
Abbott Laboratories n/a 84,288.496 54.40 19.28 3.73 3.72 n/a
Schering-Plough Corporation n/a 46,156.165 36.96 24.25 4.19 3.89 5.98
Baxter International Inc. n/a 37,709.816 24.84 21.71 3.54 3.43 8.34
Teva Pharmaceutical Industries Ltd (ADR) n/a 31,840.000 16.79 17.90 3.61 3.47 23.48
Cardinal Health, Inc. n/a 26,906.163 19.93 20.66 0.31 0.31 7.77
Medco Health Solutions Inc. n/a 22,523.128 26.18 23.05 0.52 0.49 n/a
Becton, Dickinson and Co. n/a 18,677.709 24.39 20.13 3.11 2.96 5.58
PDL BioPharma Inc. n/a 2,877.777 n/a 73.88 6.67 5.94 24.10
Medarex, Inc. n/a 1,924.479 n/a -62.54 40.86 41.21 3.45
Biosite Incorporated n/a 1,575.310 40.68 39.06 5.03 4.82 5.28
Human Genome Sciences n/a 1,365.526 n/a -5.98 48.47 26.89 7.89

- Defined by the Company - Defined by Others

Financials

  Buyer Target Combined Entity
Income Statement
Operating Items
Revenue 38,747.7 1,353.6 40,101.3
Other Revenue 1,524.1 0.0 1,524.1
Total Revenue 40,271.8 1,353.6 41,625.4
Cost of Revenue 10,361.2 320.1 10,681.3
SG&A Expense 10,952.5 476.4 11,428.9
Depreciation & Amortization 5,459.9 0.0 5,459.9
Research & Development 6,049.8 440.5 6,490.3
Interest Expense 0.0 0.0 0.0
Other Operating Expense 480.7 13.6 494.3
Unusual Expense (Income) 374.2 -48.5 325.7
Total Expenses 33,678.4 1,202.1 34,880.5
Operating Income 6,593.4 151.5 6,744.9
Non Operating Items
Interest Expense (Inc.), Net Non-Oprtng -109.3 92.9 -16.4
Other, Net 0.0 0.0 0.0
Income Before Taxes 6,484.1 244.4 6,728.5
Income Taxes 1,092.5 82.7 1,175.2
Income After Taxes 5,391.6 161.7 5,553.3
Minority Interest (IS) -536.7 0.0 -536.7
Equity in Affiliates 615.9 0.0 615.9
Net Income - Excl. Xord. Items 5,470.8 161.7 5,632.5
Net Income - Incl. Xord. Items 5,470.8 161.7 5,632.5
Income Avail. to Common 5,470.8 161.7 5,632.5
Share Items
Basic Avg. Shares Outstanding 2,696.4 237.9 2,934.3
Basic EPS - Excl. Xord. Items 2.03 0.68 1.92
Basic EPS - Incl. Xord. Items 2.03 0.68 1.92
Full Dilution Adjustment 0.0 0.0 0.0
Fully Diluted Shares Outstanding 2,696.4 241.4 2,937.8
F.D. EPS - Excl. Xord. Items 2.03 0.67 1.92
F.D. EPS - Incl. Xord. Items 2.03 0.67 1.92
Dividends Per Common Share 1.19 0.00 1.19
Balance Sheet
Assets
Cash and Equivalents 1,574.6 463.3 2,037.9
ST Investments 0.0 574.2 574.2
Accounts Receivable 0.0 280.6 280.6
Inventory 0.0 87.6 87.6
Other Current Assets 15,031.8 35.3 15,067.1
Current Assets 16,606.4 1,441.0 18,047.4
Accum D&A 0.0 0.0 0.0
PPE, Net 8,493.0 502.8 8,995.8
Goodwill & Intangibles 71,300.8 190.4 71,491.2
Long Term Investments 0.0 566.4 566.4
Other Assets 0.0 0.0 0.0
Other LT Assets 9,797.2 332.9 10,130.1
Total Assets 106,197.3 3,033.5 109,230.8
Liabilities
Accounts Payable 0.0 45.1 45.1
Payable/Accrued 10,697.2 0.0 10,697.2
Accrued Expenses 0.0 185.3 185.3
ST Debt 0.0 0.0 0.0
Curr Port of LTD & Cap Lease Oblg 3,339.0 0.0 3,339.0
Other (Current) Liabilities 0.0 131.8 131.8
Current Liab. 14,036.2 362.2 14,398.4
LT Debt 6,144.1 1,164.1 7,308.2
Total LT Debt 6,144.1 1,164.1 7,308.2
Minority Interest (BS) 300.4 0.0 300.4
Deferred Taxes 12,626.8 0.0 12,626.8
Other LT Liab. 10,816.0 42.8 10,858.8
Total Liabilities 43,923.5 1,569.1 45,492.6
Shareholders Equity
Common Stock 0.0 2.6 2.6
Additional Paid in Capital 0.0 2,713.7 2,713.7
Retained Earnings 0.0 -705.7 -705.7
Treasure Stock 0.0 -540.5 -540.5
Other Equity 62,273.8 -5.7 62,268.1
Total Equity 62,273.8 1,464.4 63,738.2
Total Liab. & Equity 106,197.3 3,033.5 109,230.8
Shares Outstanding 2,718.9 237.7 2,956.6
Cash Flow
Operating Cash Flow
CF Net Income 5,470.8 161.7 5,632.5
CF Depreciation 8,348.2 117.8 8,466.0
CF Deferred Taxes 0.0 -11.5 -11.5
Other Non-Cash Items -762.0 -26.8 -788.8
Change in Working Capital -4,038.2 -346.0 -4,384.2
Total Cash From Operating Activities 9,018.8 -104.8 8,914.0
Investing Cash Flow (not calculated)
Capital Expenditures -1,985.7 -145.6 -2,131.3
Other Investing Cash Flows 906.8 417.7 1,324.5
Total Cash From Investing Activities -1,078.9 272.1 -806.8
Financing Cash Flow (not calculated)
Dividends Paid -2,788.7 0.0 -2,788.7
Purchase Or Sale of Stock 68.3 -179.8 -111.5
Purchase and Retirement of Debt -6,862.4 638.5 -6,223.9
Other Financing Cash Flow -10.9 -310.6 -321.5
Total Cash From Financing Activities -7,994.5 148.1 -7,846.4
Exchange Rate Effects -76.5 -0.1 -76.6
Net Change in Cash -131.1 315.3 184.2
Cash Taxes Paid 0.0 2.0 2.0
Cash Interest Paid 0.0 3.8 3.8